Association of the genetic polymorphism in cytochrome P450 (CYP) 1A1 with risk of familial prostate cancer in a Japanese population: A case-control study
Department of Urology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi-City, Japan. Cancer Letters
(Impact Factor: 5.62).
07/2003; 195(2):177-83. DOI: 10.1016/S0304-3835(03)00182-4
Association between genetic polymorphisms of CYP1A1 and familial prostate cancer risk was examined by a case-control study of 185 individuals. Although the individual analysis of m1 or m2 genotype of CYP1A1 showed no significant association with prostate cancer risk, the presence of any mutated alleles significantly increased prostate cancer risk in comparison with wild-type genotypes by combination analysis (odds ratio [OR]=2.38; 95% confidence interval [CI]=1.72-3.29; P=0.0069). Furthermore, metastatic cancer had a significant association with mutated alleles of m1 and m2. These finding suggested that CYP1A1 polymorphisms has an association with prostate cancer risk, especially with progression of prostate cancer.
Available from: Solomon Paul
- "The rare homozygote m1/m1 was not seen in our control population but has been reported at 3.3% in Caucasians , 9% in Chilean  and 21% in Japanese . The frequency of the heterozygous variant w2/m2 (96%) observed in our control population is high compared to that of Japanese (32%)  and Caucasians (10%)  and the homozygous variant m2/m2 reported at 6% in Japanese  has not been observed in our study population. Hence the difference in ethnicity could account for difference in the observations. "
[Show abstract] [Hide abstract]
ABSTRACT: CYP1A1 activates environmental procarcinogens and catalyzes oxidative metabolism of estrogens and is likely to play an important role in the etiology of prostate cancer. To evaluate this phenomenon, the association between two single nucleotide polymorphisms (A to G transition in exon7 leading to amino acid substitution Ile462Val and T3801C at 3'UTR) of CYP1A1 gene in prostate cancer were analyzed in a case-control study of 100 individuals in South Indian population. The estimated relative risk was significantly high for individuals with w1/m1 genotype at 3'UTR of CYP1A1 gene (OR-4.64; 95%CI = 1.51-14.86; P < 0.01) whereas the CYP1A1 Ile/Val genotype (w2/m2) on exon 7 was found to be associated with a decreased risk for prostate cancer (OR-0.17; 95%CI = 0.02-0.89; P=0.03). A Stratified analysis of the genotypes with age of onset and tumor grade showed the w1/m1 genotype to be significantly associated with an early age of onset; however the tumor grades did not have significant association with the variant genotypes. Thus the present study indicates that individuals with the variant w1/m1 genotype exhibit an increased risk while those with w2/m2 genotype exhibit a decreased risk for prostate cancer.
Cancer biomarkers: section A of Disease markers 01/2005; 1(4-5):251-8. · 1.72 Impact Factor
Available from: dceg.cancer.gov
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 02/1981; 78:1-19.
[Show abstract] [Hide abstract]
ABSTRACT: The paper presents the design and the experiments performed for integration of a micromechanical voltage tunable Fabry-Perot interferometer structure with a silicon p-n photodiode in order to obtain a tunable optical sensor. In our approach, the top mirror of the Fabry-Perot cavity is an Au/SiO<sub>2</sub> movable membrane, formed by anisotropic etching of <111>-oriented Si wafers. The air-silicon surface acts as the lower mirror. To improve the bottom mirror reflectivity, an An layer can be deposited by electroplating. The upper movable mirror can be electrostatically actuated. This Fabry-Perot interferometer was realized on the top of a p-n photodiode.
Semiconductor Conference, 2003. CAS 2003. International; 01/2003
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.